Mr. Swapan Kakumanu reports

NETRAMARK APPOINTS DR. PANTELI THEOCHAROUS AS FRACTIONAL CHIEF MEDICAL OFFICER, STRENGTHENING CLINICAL LEADERSHIP TO ACCELERATE GLOBAL ADOPTION OF NETRAAI

Netramark Holdings Inc. has appointed Dr. Panteli Theocharous, FIBMS, MS, PhD, FRCPath, as fractional chief medical officer, marking an important step in the company's evolution as it advances toward broader global deployment of its NetraAI platform.

Dr. Theocharous currently serves and will continue to serve as chief therapeutics and clinical strategy officer (CTCSO) and president of Europe at Worldwide Clinical Trials, bringing Netramark deep expertise across clinical development, therapeutic strategy and global trial execution. His appointment reinforces Netramark's commitment to integrating world-class clinical leadership into its AI-driven (artificial intelligence) approach to transforming clinical trials.

In his role, Dr. Theocharous will work closely with Netramark's executive team to guide clinical strategy and the translation of NetraAI insights into actionable decisions across trial design, patient stratification and enrichment.

"This is an important appointment for Netramark. Dr. Theocharous operates at a high level of clinical strategy within the global drug development ecosystems. His decision to join us reflects both the strength of our technology and the growing recognition that the future of clinical trials will be driven by explainable AI," said George Achilleos, chief executive officer of Netramark. "As we deepen our collaboration across the industry, we believe his perspective will be instrumental in bridging advanced analytics with real-world clinical and regulatory decision making."

"Netramark is tackling a fundamental problem in clinical development -- the inability of conventional approaches to fully account for patient variability," said Dr. Theocharous. "The NetraAI platform offers a differentiated, clinically meaningful way to understand treatment response at a deeper level. I am excited to support the company as it scales its impact and works with sponsors to improve the probability of success in clinical trials."

This appointment comes at a time of increasing industry focus on improving trial efficiency, reducing failure rates in late-stage studies and enabling more precise, data-driven development strategies. Netramark believes that integrating advanced AI with experienced clinical leadership is essential to realizing this shift.

The company would like to extend its sincere appreciation to its outgoing chief medical officer, Dr. Larry Alphs, for his valuable contributions to Netramark's clinical and scientific advancement. Dr. Alphs will continue to support the company as an adviser, ensuring continuity and continuing strategic input as Netramark enters its next phase of growth.

About NetraAI

In contrast to other AI-based methods, NetraAI is uniquely engineered to include focus mechanisms that separate small data sets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. NetraAI uses explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses and adverse events), potentially increasing the likelihood of a clinical trial's success. Many other AI methods lack these focus mechanisms and assign every patient to a class, often leading to overfitting, which drowns out critical information that could have been used to improve a trial's chance of success.

About Netramark Holdings Inc.

Netramark is a company focused on being a leader in the development of generative artificial intelligence/machine learning (ML) solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows Netramark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that Netramark can work with much smaller data sets and accurately segment diseases into different types as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

We seek Safe Harbor.